Method for purifying waveform protein

By combining non-denatment and denaturing purification methods, the purification process of vimentin is simplified, the problems of complex operation and high cost in the prior art are solved, and efficient and low-cost vimentin purification is achieved, suitable for oncology and cytoskeleton dynamics. Field of study.

CN119080907APending Publication Date: 2024-12-06SHANDONG UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411206384.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing vimentin purification methods are complex in operation, high in cost and low in purification efficiency, making it difficult to meet experimental needs.

Method used

Using a combination of non-denatment purification and denaturing purification, initial rupture and centrifugation were performed using Tris-HCl buffer without urea, followed by denaturing and purification using urea-containing buffer and gradient elution through Hitrap MMC columns, simplifying Procedures and improve purity.

Benefits of technology

It greatly simplifies operational steps and time, reduces experimental costs, improves the purity of vimentin, and makes it more in line with physiological state, and is suitable for the fields of oncology and cytoskeleton dynamics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080907A_ABST
    Figure CN119080907A_ABST
Patent Text Reader

Abstract

The invention relates to a waveform protein purification method. The method comprises non-denaturation purification and denaturation purification. According to the waveform protein purification method disclosed by the invention, non-denaturation purification and denaturation purification are combined, two times of column chromatography are reduced, operation steps are simplified, and meanwhile, a complex buffer solution does not need to be used, so that the preparation and operation time is greatly shortened, and the experiment cost is saved. The purification method of the waveform protein can also improve the purity of the target protein, and the obtained waveform protein is a non-recombinant waveform protein and is more in line with the waveform protein generated by an organism in a physiological state.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of protein extraction, and in particular to a method for purifying vimentin. Background Art

[0002] Vimentin (VIM) is a protein of intermediate filaments, with a central α-helical domain, a non-helical amino group at the front end, and a carboxyl group at the end. Vimentin can provide elasticity that microtubules and actin do not have, can maintain the integrity of the cytoskeleton, and is one of the important components of the cytoskeleton.

[0003] J Kraxner et al. (J Kraxner, C Lorenz, J Menzel, I Parfentev, I Silbern, M Denz, H Urlaub, B Schwappach, S Kster, Post-translational modifications soften vimentin intermediate filaments) purified recombinant VIM lacking glycine-cysteine ​​in the rod domain and purified vimentin by beads (immunoprecipitation method). The purification efficiency is relatively high, but the cost is high, and it has not been confirmed whether this purification method has an effect on other physiological functions related to vimentin.

[0004] Vermeire et al. (Vermeire, PJ., Lilina, AV, Hashim, HM et al. Molecular structure of soluble vimentin tetramers. Sci Rep 13, 8841 (2023)) disclosed a method for purifying vimentin, using a buffer system of 20mM Tris-HCl pH 7.5, 10mM MgCl2, 0.1% Triton X-100, 5% Sigmafast inhibitor mixture (Sigma-Aldrich, Overijse, Belgium and 100U cryoenzyme (cold-active nuclease (Takara Bio Europe SAS, Saint-Germain-en-Laye, France), using ultrasound for lysis, and then resuspending the precipitate in a buffer system containing 8M urea after centrifugation to purify vimentin. This method requires two chromatography columns, and the operation and configuration of the buffer system are very complicated and time-consuming, the consumables are huge, and the cost is high.

[0005] Laura Schaedel et al (Laura Schaedel,Charlotta Lorenz,Anna V.Schepers,Stefan Klumpp and Sarah The vimentin purification method disclosed in (Vimentin intermediate filaments stabilizedynamic microtubules by direct interactions) is almost the same as the first method mentioned above, except that the storage buffer system is relatively more complicated, and there are also problems such as complex operation and high cost. Summary of the invention

[0006] Problem that the invention aims to solve

[0007] In view of the above problems existing in the prior art, the object of the present invention is to provide a method for purifying vimentin which has simple operation, low cost and good purification effect.

[0008] Solutions for solving problems

[0009] The present invention provides a method for purifying vimentin, which comprises non-denaturing purification and denaturing purification.

[0010] Preferably, the method comprises the following steps:

[0011] (1) disrupting and lysing bacteria expressing vimentin;

[0012] (2) Denaturation purification.

[0013] Preferably, step (1) comprises using a buffer system without urea to disrupt the bacteria expressing vimentin, followed by centrifugation, and discarding the supernatant;

[0014] Preferably, the urea-free buffer system is a Tris-HCl buffer;

[0015] Preferably, the crushing is low temperature and high pressure crushing.

[0016] Preferably, the concentration of the Tris-HCl buffer is 5-15 mM, more preferably, the concentration of the Tris-HCl buffer is 10 mM;

[0017] Preferably, the pH of the Tris-HCl buffer is 7-9, more preferably, the pH of the Tris-HCl buffer is 8.4;

[0018] Preferably, the low temperature is 1-10°C, more preferably, the low temperature is 4°C;

[0019] Preferably, the high pressure is 900-1200 mBar, more preferably, the high pressure is 1000 mBar;

[0020] Preferably, the centrifugal speed is 1000-15000 rpm, more preferably, the centrifugal speed is 12000 rpm;

[0021] Preferably, the centrifugation time is 30-90 minutes, more preferably, the centrifugation time is 60 minutes.

[0022] Preferably, the denaturation purification in step (2) is to resuspend the precipitate using a urea-containing buffer system and then centrifuge to obtain the supernatant;

[0023] Preferably, the urea-containing buffer system comprises urea and Tris-HCl buffer.

[0024] Preferably, the concentration of urea is 5-10M, more preferably, the concentration of urea is 8M;

[0025] Preferably, the concentration of the urea Tris-HCl buffer is 5-15 mM, more preferably, the concentration of the Tris-HCl buffer is 10 mM;

[0026] Preferably, the pH of the Tris-HCl buffer is 7-9, more preferably, the pH of the Tris-HCl buffer is 8.4;

[0027] Preferably, the centrifugal speed is 10000-15000 rpm, more preferably, the centrifugal speed is 12000 rpm;

[0028] Preferably, the centrifugation time is 15-45 minutes, more preferably, the centrifugation time is 30 minutes.

[0029] Preferably, the method further comprises the steps of:

[0030] (3) Using a Hitrap MMC column, perform gradient elution on the supernatant obtained in step (2).

[0031] Preferably, the gradient elution is to adjust the concentration of mobile phase A from 100% to 0%, and the concentration of mobile phase B from 0% to 100%, and to elute at a constant flow rate;

[0032] Preferably, the mobile phase A comprises one or more of urea, EDTA, and Tris-HCl.

[0033] Preferably, the pH of the mobile phase A is 7-9, more preferably, the pH of the mobile phase A is 8.4;

[0034] Preferably, the mobile phase B comprises one or more of urea, EDTA, MES, and KCl;

[0035] Preferably, the pH of the mobile phase B is 5-7, more preferably, the pH of the mobile phase B is 6;

[0036] Preferably, the constant flow rate is 3-8; more preferably, the constant flow rate is 5.

[0037] The present invention also provides a vimentin protein prepared according to the method.

[0038] The present invention also provides a use of the vimentin in the field of oncology and / or cytoskeleton dynamics.

[0039] Effects of the Invention

[0040] The vimentin purification method of the present invention combines non-denaturing purification with denaturing purification, reduces two column chromatography steps, simplifies the operation steps, and does not require the use of complex buffers, thereby greatly shortening the preparation and operation time and saving experimental costs. The vimentin purification method of the present invention can also improve the purity of the target protein, and the obtained vimentin is more consistent with the vimentin produced by the body under physiological conditions. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 Flow chart of the vimentin purification method.

[0042] Figure 2 These are the SDS-PAGE results before and after induction, the supernatant of step 1, and the precipitate of step 1.

[0043] Figure 3 The figures are the SDS-PAGE results of vimentin in step 1 (left) and step 2 (right).

[0044] Figure 4 It is the UV280 absorption peak after gradient elution using Hitrap MMC column.

[0045] Figure 5 This is the SDS-PAGE result of vimentin after gradient elution using Hitrap MMC column.

[0046] Figure 6 The SDS-PAGE results of vimentin purified by the old process (left) and the present invention (right) are shown.

[0047] Figure 7 This is the UV280 absorption peak and SDS-PAGE result of vimentin purified by DEAE column using the old process.

[0048] Figure 8This is the UV280 absorption peak and SDS-PAGE result of vimentin purified by Hitrap MMC column using the old process. DETAILED DESCRIPTION

[0049] In order to make the technical solutions and beneficial effects of the present invention more clearly understandable, the following is a detailed description by listing specific embodiments. The drawings are not necessarily drawn to scale, and local features may be enlarged or reduced to more clearly show the details of the local features; unless otherwise defined, the technical and scientific terms used herein have the same meanings as those in the technical field to which this application belongs.

[0050] The present invention provides a method for purifying vimentin, which comprises non-denaturing purification and denaturing purification.

[0051] In certain embodiments, the method comprises the steps of:

[0052] (1) disrupting and lysing bacteria expressing vimentin;

[0053] (2) Denaturation purification.

[0054] In certain embodiments, step (1) comprises disrupting the bacteria expressing vimentin using a buffer system that does not contain urea, centrifuging, and discarding the supernatant.

[0055] In certain embodiments, the sequence of the vimentin protein in step (1) is as shown in SEQ ID No.1.

[0056] SEQ ID No.1:

[0057] ATGTCCACCAGGTCCGTGTCCTCGTCCTCCTACCGCAGGATGTTCGGCGGCCCGGGC

[0058] ACCGCGAGCCGGCCGAGCTCCAGCCGGAGCTACGTGACTACGTCCACCCGCACCTACA

[0059] GCCTGGGCAGCGCGCTGCGCCCCAGCACCAGCCGCAGCCTCTACGCCTCGTCCCCGGG

[0060] CGGCGTGTATGCCACGCGCTCCTCTGCCGTGCGCCTGCGGAGCAGCGTGCCCGGGGTGC

[0061] GGCTCCTGCAGGACTCGGTGGACTTCTCGCTGGCCGACGCCATCAACACCGAGTTCAA

[0062] GAACACCCGCACCAACGAGAAGGTGGAGCTGCAGGAGCTGAATGACCGCTTCGCCAAC

[0063] TACATCGACAAGGTGCGCTTCCTGGAGCAGCAGAATAAGATCCTGCTGGCCGAGCTCGA

[0064] GCAGCTCAAGGGCCAAGGCAAGTCGCGCCTGGGGGACCTCTACGAGGAGGAGATGCG

[0065] GGAGCTGCGCCGGCAGGTGGACCAGCTAACCAACGACAAAGCCCGCGTCGAGGTGGA

[0066] GCGCGACAACCTGGCCGAGGACATCATGCGCCTCCGGGAGAAATTGCAGGAGGAGATG

[0067] CTTCAGAGAGAGGAAGCCGAAAACACCCTGCAATCTTTCAGACAGGATGTTGACAATG

[0068] CGTCTCTGGCACGTCTTGACCTTGAACGCAAAGTGGAATCTTTGCAAGAAGAGATTGCC

[0069] TTTTTGAAGAAACTCCACGAAGAGGAAATCCAGGAGCTGCAGGCTCAGATTCAGGAAC

[0070] AGCATGTCCAAATCGATGTGGATGTTTCCAAGCCTGACCTCACGGCTGCCCTGCGTGAC

[0071] GTACGTCAGCAATATGAAAGTGTGGCTGCCAAGAACCTGCAGGAGGCAGAAGAATGGT

[0072] ACAAATCCAAGTTTGCTGACCTCTCTGAGGCTGCCAACCGGAACAATGACGCCCTGCGC

[0073] CAGGCAAAGCAGGAGTCCACTGAGTACCGGAGACAGGTGCAGTCCCTCACCTGTGAAG

[0074] TGGATGCCCTTAAAGGAACCAATGAGTCCCTGGAACGCCAGATGCGTGAAATGGAAGA

[0075] GAACTTTGCCGTTGAAGCTGCTAACTACCAAGACACTATTGGCCGCCTGCAGGATGAGA

[0076] TTCAGAATATGAAGGAGGAAATGGCTCGTCACCTTCGTGAATACCAAGACCTGCTCAAT

[0077] GTTAAGATGGCCCTTGACATTGAGATTGCCACCTACAGGAAGCTGCTGGAAGGCGAGGA

[0078] GAGCAGGATTTCTCTGCCTCTTCCAAACTTTTCCTCCCTGAACCTGAGGGAAAACTAATCT

[0079] GGATTCACTCCCTCTGGTTGATACCCACTCAAAAAGGACACTTCTGATTAAGACGGTTG

[0080] AAACTAGAGATGGACAGGTTATCAACGAAACTTCTCAGCATCACGATGACCTTGAATAA In certain embodiments, step (1) is the non-denaturing purification.

[0081] In certain embodiments, the urea-free buffer system is a Tris-HCl buffer.

[0082] In certain embodiments, the fragmentation is low temperature and high pressure fragmentation.

[0083] In certain embodiments, the concentration of the Tris-HCl buffer is 5-15 mM.

[0084] In certain embodiments, the concentration of the Tris-HCl buffer is 5 mM, or 6 mM, or 7 mM, or 8 mM, or 9 mM, or 10 mM, or 11 mM, or 12 mM, or 13 mM, or 14 mM, or 15 mM.

[0085] In certain embodiments, the concentration of the Tris-HCl buffer is 10 mM.

[0086] In certain embodiments, the pH of the Tris-HCl buffer is 7-9.

[0087] In certain embodiments, the pH of the Tris-HCl buffer is 7, or 7.1, or 7.2, or 7.3, or 7.4, or 7.5, or 7.6, or 7.7, or 7.8, or 7.9, or 8, or 8.1, or 8.2, or 8.3, or 8.4, or 8.5, or 8.6, or 8.7, or 8.8, or 8.9, or 9.

[0088] In certain embodiments, the pH of the Tris-HCl buffer is 8.4.

[0089] In certain embodiments, the low temperature is 1-10°C.

[0090] In certain embodiments, the low temperature is 1°C, or 2°C, or 3°C, or 4°C, or 5°C, or 6°C, or 7°C, or 8°C, or 9°C, or 10°C.

[0091] In certain embodiments, the low temperature is 4°C.

[0092] In certain embodiments, the high pressure is 900-1200 mBar.

[0093] In certain embodiments, the high pressure is 900mBar, or 910mBar, or 920mBar, or 930mBar, or 940mBar, or 950mBar, or 960mBar, or 970mBar, or 980mBar, or 990mBar, or 1000mBar, or 1010mBar, or 1020mBar, or 1030mBar, or 1040mBar, or 1050mBar, or 1060mBar, or 1070mBar, or 1080mBar, or 1090mBar, or 1100mBar, or 1110mBar, or 1120mBar, or 1130mBar, or 1140mBar, or 1150mBar, or 1160mBar, or 1170mBar, or 1180mBar, or 1190mBar, or 1200mBar.

[0094] In certain embodiments, the high pressure is 1000 mBar.

[0095] In certain embodiments, the centrifugation speed is 1000-15000 rpm.

[0096] In certain embodiments, the centrifugal rotation speed is 1000 rpm, or 2000 rpm, or 3000 rpm, or 4000 rpm, or 5000 rpm, or 6000 rpm, or 7000 rpm, or 8000 rpm, or 9000 rpm, or 10000 rpm, or 11000 rpm, or 12000 rpm, or 13000 rpm, or 14000 rpm, or 15000 rpm.

[0097] In certain embodiments, the centrifugation speed is 12000 rpm.

[0098] In certain embodiments, the centrifugation time is 30-90 minutes.

[0099] In certain embodiments, the centrifugation time is 30 minutes, or 35 minutes, or 40 minutes, or 45 minutes, or 50 minutes, or 55 minutes, or 60 minutes, or 65 minutes, or 70 minutes, or 75 minutes, or 80 minutes, or 85 minutes, or 90 minutes.

[0100] In certain embodiments, the centrifugation time is 60 minutes.

[0101] In certain embodiments, the denaturation purification in step (2) is to resuspend the precipitate in a buffer system containing urea and then centrifuge to obtain the supernatant.

[0102] In certain embodiments, the urea-containing buffer system comprises urea and Tris-HCl buffer.

[0103] In certain embodiments, the concentration of urea is 5-10M.

[0104] In certain embodiments, the concentration of urea is 5M, or 6M, or 7M, or 8M, or 9M, or 10M.

[0105] In certain embodiments, the concentration of urea is 8M.

[0106] In certain embodiments, the concentration of the urea Tris-HCl buffer is 5-15 mM.

[0107] In certain embodiments, the concentration of the urea Tris-HCl buffer is 5 mM, or 6 mM, or 7 mM, or 8 mM, or 9 mM, or 10 mM, or 11 mM, or 12 mM, or 13 mM, or 14 mM, or 15 mM.

[0108] In certain embodiments, the concentration of the Tris-HCl buffer is 10 mM.

[0109] In certain embodiments, the pH of the Tris-HCl buffer is 7-9.

[0110] In certain embodiments, the pH of the Tris-HCl buffer is 7, or 7.1, or 7.2, or 7.3, or 7.4, or 7.5, or 7.6, or 7.7, or 7.8, or 7.9, or 8, or 8.1, or 8.2, or 8.3, or 8.4, or 8.5, or 8.6, or 8.7, or 8.8, or 8.9, or 9.

[0111] In certain embodiments, the pH of the Tris-HCl buffer is 8.4.

[0112] In certain embodiments, the centrifugation speed is 10000-15000 rpm.

[0113] In certain embodiments, the centrifugal rotation speed is 10000 rpm, or 11000 rpm, or 12000 rpm, or 13000 rpm, or 14000 rpm, or 15000 rpm.

[0114] In certain embodiments, the centrifugation speed is 12000 rpm.

[0115] In certain embodiments, the centrifugation time is 15-45 minutes.

[0116] In certain embodiments, the centrifugation time is 15 minutes, or 20 minutes, or 25 minutes, or 30 minutes, or 35 minutes, or 40 minutes, or 45 minutes.

[0117] In certain embodiments, the centrifugation time is 30 minutes.

[0118] In certain embodiments, the method further comprises the steps of:

[0119] (3) Using a Hitrap MMC column, perform gradient elution on the supernatant obtained in step (2).

[0120] In certain embodiments, the gradient elution is performed by changing the concentration of mobile phase A from 100% to 0%, and the concentration of mobile phase B from 0% to 100%, at a constant flow rate.

[0121] In certain embodiments, the mobile phase A comprises one or more of urea, EDTA, and Tris-HCl.

[0122] In certain embodiments, the mobile phase A is urea, EDTA, or Tris-HCl.

[0123] In certain embodiments, the pH of the mobile phase A is 7-9.

[0124] In some embodiments, the pH of the mobile phase A is 7, or 7.1, or 7.2, or 7.3, or 7.4, or 7.5, or 7.6, or 7.7, or 7.8, or 7.9, or 8, or 8.1, or 8.2, or 8.3, or 8.4, or 8.5, or 8.6, or 8.7, or 8.8, or 8.9, or 9.

[0125] In certain embodiments, the pH of the mobile phase A is 8.4.

[0126] In certain embodiments, the mobile phase B comprises one or more of urea, EDTA, MES, and KCl.

[0127] In certain embodiments, the mobile phase B is urea, EDTA, MES, or KCl.

[0128] In certain embodiments, the pH of the mobile phase B is 5-7.

[0129] In some embodiments, the pH of the mobile phase B is 5, or 5.1, or 5.2, or 5.3, or 5.4, or 5.5, or 5.6, or 5.7, or 5.8, or 5.9, or 6, or 6.1, or 6.2, or 6.3, or 6.4, or 6.5, or 6.6, or 6.7, or 6.8, or 6.9, or 7.

[0130] In some embodiments, the pH of mobile phase B is 6.

[0131] In certain embodiments, the constant flow rate is 3-8.

[0132] In certain embodiments, the constant flow rate is 3, or 3.5, or 4, or 4.5, or 5, or 5.5, or 6, or 6.5, or 7, or 7.5, or 8.

[0133] In some embodiments, the constant flow rate is 5.

[0134] The present invention also provides a vimentin protein prepared according to the method.

[0135] In certain embodiments, the vimentin is non-recombinant vimentin.

[0136] The present invention also provides a use of the vimentin in the field of oncology and / or cytoskeleton dynamics.

[0137] Example 1: Construction of a strain expressing vimentin

[0138] The VIM protein sequence (Gene ID: 7431, as shown in SEQ ID No. 1) was searched at NCBI (National Center for Biotechnology Information). The VIM full-length plasmid (VIM full length, the plasmid was prepared in the laboratory, the VIM genome full-length DNA was purchased from Bio-Tech, and was connected to the plasmid with pET as the vector through the restriction sites Ndel and BamH using a double restriction system) was amplified by PCR and transferred into Escherichia coli BL21 (DE3), and cultured overnight at 37°C. The next day, the Escherichia coli was transferred to a 1.5L conical flask for amplification culture, and IPTG was added 4 hours later to induce for 12 hours. The Escherichia coli BL21 (DE3) before and after induction was electrophoresed using 12% SDS-PAGE gel and the band results were analyzed. The results are as follows: Figure 2 As shown, VIM was successfully expressed in large amounts after induction.

[0139] SEQ ID No.1:

[0140]

[0141] Example 2: Initial purification of vimentin

[0142] The process of vimentin purification method is as follows Figure 1 As shown, the specific steps are as follows:

[0143] (1) Cell disruption and lysis

[0144] The E. coli prepared in Example 1 was disrupted using a low-temperature high-pressure cell disruptor (1000 mBar-1200 mBar, 4°C) using a urea-free buffer system (10 mM Tris-HCl, pH 8.4). The strain was lysed and centrifuged (12000 rpm, 60 min). The supernatant and precipitate were taken and electrophoresed using 12% SDS-PAGE gel to analyze the bands. The results are shown in FIG. Figure 2 As shown, the target protein is mostly present in the precipitate, and the supernatant contains a large amount of soluble impurity proteins.

[0145] (2) Denaturation purification

[0146] The supernatant was discarded and the precipitate was resuspended in a urea-containing buffer system (8 M urea and 10 mM Tris-HCl, pH 8.4). The resuspended liquid was centrifuged at 12000 rpm for 30 min, and the supernatant after centrifugation and the resuspended liquid of the precipitate after centrifugation were taken for electrophoresis using 12% SDS-PAGE gel and the band analysis results showed that vimentin was located in the supernatant (see Figure 3 ), and by observing the corresponding bands and comparing them with the protein molecular weight standards, it can be analyzed that its concentration and purity are very high.

[0147] Example 3: Further purification of vimentin

[0148] The supernatant prepared in Example 2 was subjected to gradient elution using a Hitrap MMC column.

[0149] (1) Use a peristaltic pump to wash the column with 25 ml of water and 50 ml of buffer (10 mM Tris-HCl, pH 8.4)

[0150] (2) Filter the sample with a 0.45 μm filter membrane before loading it onto the column, and hang the protein on the column (2 times)

[0151] (3) Use five column volumes of buffer A (8 M urea, 1 mM EDTA, 5 mM Tris-HCl, pH = 8.4) to wash away the impurities that are not bound to the Hitrap MMC column.

[0152] (4) Use a protein purifier (AKTA) equipped with a Hitrap MMC column for liquid chromatography. Fill pump A with buffer A and pump B with buffer B (8 M urea, 1 mM EDTA, 5 mM MES, 1 M KCl, pH = 6.0)

[0153] (5) Set the program parameters of the AKTA protein purification system, set the concentration of pump A from 100% to 0%, and the concentration of pump B from 0% to 100%, and start elution at a constant flow rate of "5". When the AKTA program curve detects a significant change in the UV curve, it means that the protein has been successfully eluted.

[0154] (6) The mAU-t curve generated by the AKTA protein purification system program analysis software was further analyzed. Figure 4 As shown, 4 main UV280 absorption peaks were obtained. The salt ion concentration at peak 1 was about 112mM KCl, the salt ion concentration at peak 2 was about 150mM KCl, the salt ion concentration at peak 3 was about 206mM KCl, and the salt ion concentration at peak 4 was about 289mM KCl. The product purified by Hitrap MMC column was subjected to protein electrophoresis using 12% SDS-PAGE gel to analyze the bands. The results Figure 5 As shown in FIG. 1 , it can be seen that peaks 1 to 4 are all large amounts of VIM. Comparison of the SDS-PAGE results of the vimentin purified by the old process and the present invention is shown in FIG. Figure 6 shown.

[0155] Comparative Example 1: Purification of Vimentin Using the Old Process

[0156] (1) Cell disruption and lysis

[0157] The E. coli prepared in Example 1 was disrupted by a low temperature high pressure cell disruptor (1000 mBar-1200 mBar, 4° C.) The buffer system was 8 M urea, 5 mM Tris, pH 7.6, 1 mM EDTA, 10 mM β-Me, 0.4 mM PMSF.

[0158] (2) DEAE column purification

[0159] The supernatant prepared in step 1 was subjected to gradient elution using a DEAE column.

[0160] The DEAE column was washed with 25 ml of double distilled water and 25 ml of buffer A (8 M urea, 5 mM Tris, pH 7.6, 1 mM EDTA, 10 mM β-Me, 0.4 mM PMSF) by a peristaltic pump.

[0161] The sample was filtered with a 0.45 μm filter membrane before loading onto the column, and the protein was loaded onto the column (twice).

[0162] Five column volumes of buffer A (8 M urea, 5 mM Tris, pH 7.6, 1 mM EDTA, 10 mM β-Me, 0.4 mM PMSF) were used to wash away the impurities that were not bound to the Hitrap MMC column.

[0163] Use a protein purifier (AKTA) equipped with a DEAE column for liquid chromatography. Fill pump A with buffer A (8 M urea, 5 mM Tris, pH 7.6, 1 mM EDTA, 10 mM β-Me, 0.4 mM PMSF) and pump B with buffer B (8 M urea, 5 mM Tris, pH 7.6, 0.3 M NaCl, 1 mM EDTA, 10 mM β-Me, 0.4 mM PMSF).

[0164] Set the program parameters of the AKTA protein purification system, set the concentration of pump A from 100% to 0%, and the concentration of pump B from 0% to 100%, and start elution at a constant flow rate of "5". When the AKTA program curve detects a significant change in the UV curve, it means that the protein has been successfully eluted.

[0165] Further analysis of the mAu-t curve generated by the AKTA protein purification system program analysis software yielded eight major UV280 absorption peaks, with the salt ion concentration at peak 1 (14 ml) being approximately 43.8 mM KCl, the salt ion concentration at peak 2 (26 ml) being approximately 67.8 mM KCl, the salt ion concentration at peak 3 (41 ml) being approximately 94.2 mM KCl, the salt ion concentration at peak 4 (57 ml) being approximately 118.5 mM KCl, the salt ion concentration at peak 5 (65 ml) being approximately 156.6 mM KCl, the salt ion concentration at peak 6 (75 ml) being approximately 187.5 mM KCl, the salt ion concentration at peak 7 (79 ml) being approximately 220.8 mM KCl, and the salt ion concentration at peak 8 (82 ml) being approximately 295.5 mM KCl. The product purified by the DEAE column was subjected to protein electrophoresis using 12% SDS-PAGE gel, and the results are as follows: Figure 7 As shown. Analyzing the bands, it can be seen that peaks 1-5 are all large amounts of VIM, but also have a large amount of impurity bands. The five groups of samples with high VIM concentrations were mixed, loaded using a peristaltic pump, and further purified using a Hitrap MMC column.

[0166] The method of using the Hitrap MMC column is the same as in Example 3. The SDS-PAGE verification results are as follows: Figure 8 As shown, the purity of VIM obtained by purification using the old process is low.

[0167] It should be understood that the above embodiments are exemplary and are not intended to include all possible implementations included in the claims. Various modifications and changes may be made on the basis of the above embodiments without departing from the scope of the present disclosure. Similarly, the various technical features of the above embodiments may be arbitrarily combined to form other embodiments of the present invention that may not be explicitly described. Therefore, the above embodiments only express several implementations of the present invention and do not limit the scope of protection of the patent of the present invention.

Claims

1. A method for purifying vimentin, characterized in that: The method includes native purification and denaturing purification.

2. The method according to claim 1, characterized in that The method comprises the following steps: (1) disrupting and lysing bacteria expressing vimentin; (2) Denaturation purification.

3. The method according to claim 2, characterized in that Step (1) comprises using a buffer system without urea to disrupt the bacteria expressing vimentin, centrifuging, and discarding the supernatant; Preferably, the urea-free buffer system is a Tris-HCl buffer; Preferably, the cell lysis method is low temperature and high pressure disruption.

4. The method according to claim 3, characterized in that The concentration of the Tris-HCl buffer is 5-15 mM, more preferably, the concentration of the Tris-HCl buffer is 10 mM; Preferably, the pH of the Tris-HCl buffer is 7-9, more preferably, the pH of the Tris-HCl buffer is 8.4; Preferably, the low temperature is 1-10°C, more preferably, the low temperature is 4°C; Preferably, the high pressure is 900-1200 mBar, more preferably, the high pressure is 1000 mBar; Preferably, the centrifugal speed is 10000-15000 rpm, more preferably, the centrifugal speed is 12000 rpm; Preferably, the centrifugation time is 30-90 minutes, more preferably, the centrifugation time is 60 minutes.

5. The method according to claim 2, characterized in that: The denaturation purification in step (2) is to resuspend the precipitate in a buffer system containing urea and then centrifuge to obtain the supernatant; Preferably, the urea-containing buffer system comprises urea and Tris-HCl buffer.

6. The method according to claim 5, characterized in that The concentration of the urea is 5-10M, more preferably, the concentration of the urea is 8M; Preferably, the concentration of the urea Tris-HCl buffer is 5-15 mM, more preferably, the concentration of the Tris-HCl buffer is 10 mM; Preferably, the pH of the urea Tris-HCl buffer is 7-9, more preferably, the pH of the Tris-HCl buffer is 8.4; Preferably, the centrifugal speed is 10000-15000 rpm, more preferably, the centrifugal speed is 12000 rpm; Preferably, the centrifugation time is 15-45 minutes, more preferably, the centrifugation time is 30 minutes.

7. The method according to claim 2, characterized in that The method further comprises the steps of: (3) Using a Hitrap MMC column, perform gradient elution on the supernatant obtained in step (2).

8. The method according to claim 7, characterized in that The gradient elution is to change the concentration of mobile phase A from 100% to 0%, and the concentration of mobile phase B from 0% to 100%, and to elute at a constant flow rate; Preferably, the mobile phase A comprises one or more of urea, EDTA, and Tris-HCl. Preferably, the pH of the mobile phase A is 7-9, more preferably, the pH of the mobile phase A is 8.4; Preferably, the mobile phase B comprises one or more of urea, EDTA, MES, and KCl; Preferably, the pH of the mobile phase B is 5-7, more preferably, the pH of the mobile phase B is 6; Preferably, the constant flow rate is 3-8; more preferably, the constant flow rate is 5.

9. Vimentin prepared according to the method of any one of claims 1-8.

10. Use of the vimentin according to claim 9 in the field of oncology and / or cytoskeletal dynamics.

Citation Information

Patent Citations

  • Large-scale preparation method of human bone morphogenetic protein 2

    CN107759683A

  • Purification method of waveform protein

    CN114702565A

  • Preparation method of citrullinated waveform protein

    CN116589556A